BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu KD, Liu GY, Chen CM, Li JW, Wu J, Lu JS, Shen ZZ, Shao ZM. Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule. Oncologist 2013;18:511-7. [PMID: 23635560 DOI: 10.1634/theoncologist.2012-0057] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Wu S, Wang Y, Li J, Zhang N, Mo M, Klimberg S, Kaklamani V, Cochet A, Shao Z, Cheng J, Liu G. Subtype-Guided 18 F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study. Oncologist 2020;25:e626-33. [PMID: 32297448 DOI: 10.1634/theoncologist.2019-0583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Li L, Chen M, Zheng S, Li H, Chi W, Xiu B, Zhang Q, Hou J, Wang J, Wu J. Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy. Front Oncol 2021;11:592393. [PMID: 34336634 DOI: 10.3389/fonc.2021.592393] [Reference Citation Analysis]
3 Sikov WM. Assessing the role of platinum agents in aggressive breast cancers. Curr Oncol Rep 2015;17:3. [PMID: 25665554 DOI: 10.1007/s11912-014-0428-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
4 Zhang Y, Mo M, Li J, Zhou Y, Wu J, Yu K, Shen Z, Shao Z, Liu G. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study. European Journal of Surgical Oncology (EJSO) 2016;42:1146-52. [DOI: 10.1016/j.ejso.2016.05.039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Ding J, Yang Y, Jiang L, Wu W, Shao Z. Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab. Oncotarget 2017;8:56626-34. [PMID: 28915617 DOI: 10.18632/oncotarget.17993] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Shi G, Cheng Y, Zhang Y, Guo R, Li S, Hong X. Long non-coding RNA LINC00511/miR-150/MMP13 axis promotes breast cancer proliferation, migration and invasion. Biochim Biophys Acta Mol Basis Dis 2021;1867:165957. [PMID: 33031905 DOI: 10.1016/j.bbadis.2020.165957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Zhu T, Liu CL, Zhang YF, Liu YH, Xu FP, Zu J, Zhang GC, Li XR, Liao N, Wang K. A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer. Breast Cancer Res Treat 2016;156:117-24. [PMID: 26936755 DOI: 10.1007/s10549-016-3735-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
8 De Iuliis F, Salerno G, Corvino R, D'Aniello D, Cefalì K, Taglieri L, Lanza R, Scarpa S. Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer. Clin Breast Cancer 2017;17:34-40. [PMID: 27435626 DOI: 10.1016/j.clbc.2016.06.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
9 van Ramshorst MS, van Werkhoven E, Mandjes IAM, Schot M, Wesseling J, Vrancken Peeters MTFD, Meerum Terwogt JM, Bos MEM, Oosterkamp HM, Rodenhuis S, Linn SC, Sonke GS. Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. Eur J Cancer 2017;74:47-54. [PMID: 28335887 DOI: 10.1016/j.ejca.2016.12.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
10 Bychkovsky BL, Dizon DS, Sikov WM. Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy. Clin Obstet Gynecol 2016;59:756-71. [PMID: 27741213 DOI: 10.1097/GRF.0000000000000237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
11 Huang L, Chen S, Yang W, Xu B, Huang T, Yang H, Zheng H, Wang Y, Song E, Zhang J, Cui S, Pang D, Tang L, Lei Y, Geng C, Shao Z. Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial. Oncotarget 2015;6:18683-92. [PMID: 26084292 DOI: 10.18632/oncotarget.4337] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
12 Xie Y, Wu S, Zhang Y, Li J, Mo M, Shao Z, Liu G. Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer. Front Oncol 2021;11:686591. [PMID: 34168999 DOI: 10.3389/fonc.2021.686591] [Reference Citation Analysis]
13 Lee J, Solimando DA Jr, Waddell JA. Paclitaxel, Carboplatin, and trastuzumab. Hosp Pharm 2014;49:913-9. [PMID: 25477563 DOI: 10.1310/hpj4910-913] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Wu S, Wang Y, Zhang N, Li J, Xu X, Shen J, Liu G. Intraoperative Touch Imprint Cytology in Targeted Axillary Dissection After Neoadjuvant Chemotherapy for Breast Cancer Patients with Initial Axillary Metastasis. Ann Surg Oncol 2018;25:3150-7. [PMID: 30083833 DOI: 10.1245/s10434-018-6548-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Huang L, Chen S, Yao L, Liu G, Wu J, Shao Z. Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer. Int J Nanomedicine 2015;10:1969-75. [PMID: 25792830 DOI: 10.2147/IJN.S77000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
16 Li JW, Mo M, Yu KD, Chen CM, Hu Z, Hou YF, Di GH, Wu J, Shen ZZ, Shao ZM, Liu GY. ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy. PLoS One 2014;9:e114646. [PMID: 25504233 DOI: 10.1371/journal.pone.0114646] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]